amifloxacin has been researched along with imipenem, anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alderman, HC; Alvarez, ME; Bodey, GP; Ho, DH; Hoy, JF; Rolston, KV | 1 |
| Alvarez, ME; Bodey, GP; Hsu, KC; Rolston, KV | 1 |
2 other study(ies) available for amifloxacin and imipenem, anhydrous
| Article | Year |
|---|---|
In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Positive Bacteria; Humans; Imipenem; Lactams; Listeria monocytogenes; Neoplasms; Staphylococcus; Streptococcus; Thienamycins | 1986 |
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
Topics: Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Ciprofloxacin; Cross Infection; Fluoroquinolones; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Neoplasms; Quinolines; Thienamycins | 1986 |